Direct-acting antiviral (DAA) exposure may not be associated with higher rates of any serious adverse events when used for hepatitis C virus (HCV) treatment, according to a study published in JAMA Network Open. At this time, there are approximately 2.4 million individuals living in the United States who are infected with HCV. Further, 28% of…
Fibronectin may be a potential marker for hepatitis B surface antigen seroclearance.
In a large cohort of patients with HCV, the use of DAA was associated with significantly lower incidence and risk for subsequent diabetes.
Hepatitis B e antigen prevalence and other hepatitis B virus markers decline with age and differ by race with HBeAg persisting longer among Asian people.
The FDA has approved Mavyret for the treatment of all 6 genotypes of hepatitis C virus in children 12 to 17 years old or weighing at least 45kg.
The epidemic of opioid use disorder has led to substantial increases in new cases of HCV and HIV infection, as well as hospitalizations for other OUD-related infections.
In onsite HCV care delivered to PWID in opioid agonist therapy programs, a greater adherence was associated with directly observed therapy when compared with self-administered individual treatment.
Treatment with DAAs before liver transplantation is associated with improved outcome and appears to be safe in patients with decompensated hepatitis C-related cirrhosis.
There was no significant effect of maternal tenofovir use for the prevention of mother-to-child transmission of HBV on bone mineral density in either the mother or child 1 year after delivery.
Patients with TB and HBV co-infection should be given antiviral treatment for HBV when anti-TB therapy is initiated.
